Impact of Dexmedetomidine on Hemodynamics, Plasma Catecholamine Levels, and Delirium Incidence Among Intubated Patients in the ICU--A Randomized Controlled Trial
Li Qiao,Zheng Wang,Jian Shen,Xiaohui Xing,Hongxun Yuan
DOI: https://doi.org/10.2147/tcrm.s471229
2024-09-30
Therapeutics and Clinical Risk Management
Abstract:Li Qiao, Zheng Wang, Jian Shen, Xiaohui Xing, Hongxun Yuan Department of Intensive Care Unit, Peking University International Hospital, Beijing, People's Republic of China Correspondence: Hongxun Yuan, Department of Intensive Care Unit, Peking University International Hospital, No. 1 of Life Park Road, Life Science Park of Zhong Guancun, Changping District, Beijing, 102206, People's Republic of China, Tel +86 10 69006109, Email Objective: To investigate the impact of various sedative medications on hemodynamics and plasma levels of epinephrine (E) and norepinephrine (NE) in mechanically ventilated patients postoperatively in the intensive care unit (ICU). Methods: Ninety-seven patients admitted to the ICU undergoing postoperative mechanical ventilation with tracheal intubation and continuous analgesic sedation following general anesthesia were randomly assigned to either the observation group (dexmedetomidine) (n = 49) or the control group (propofol) (n = 48) in this randomized controlled trial. Upon transfer to the ICU, vital signs (heart rate [HR], respiratory rate [RR], mean arterial pressure [MAP]) were recorded prior to the initiation of the sedation treatment (T0), at one-hour post sedation (T1) and two hours following tracheal extubation (T2), plasma levels of epinephrine (E) and norepinephrine (NE) were measured at these time points. The incidence of delirium was recorded in both groups. Results: MAP between the two groups at both T0 and T1 At T2 plasma NE and HR were found to be lower in the observation group compared to the control group ( P < 0.001). Among the patients receiving antihypertensive medication in the ICU, NE levels were significantly lower in the observation group compared to the control group ( P = 0.019 ) Among the patients not receiving antihypertensive medication, both NE (P < 0.001 ) and MAP (P = 0.001 ) levels were lower in the observation group compared to the control group. The incidence of delirium in the observation group (dexmedetomidine) was not significantly different from that in the control group (propofol). Conclusion: With dexmedetomidine sedation, blood pressure fluctuated less, plasma catecholamine levels were lower, and sympathetic inhibition was stronger in patients before and after extubation. However, it did not significantly reduce the incidence of postoperative delirium. Keywords: delirium, intensive care unit, hemodynamics, plasma norepinephrine, delirium Sedation plays a crucial role in alleviating agitation and anxiety among patients in the ICU, 1 with the primary objective of promoting patient cooperation with treatment and facilitating calm expression of their needs, particularly for analgesia. 2 Current clinical guidelines advocate for the use of sedative medications such as propofol, benzodiazepines (most commonly midazolam and lorazepam), 3 and dexmedetomidine, which mitigates sympathetic stress. Studies have demonstrated that maintaining patients under mild sedation can contribute to improved clinical outcomes, including reduced duration of mechanical ventilation and ICU treatment. Therefore, it is recommended to aim for mild sedation whenever feasible for patients in the ICU. 3 Dexmedetomidine is a highly selective α2 adrenergic receptor agonist, primarily targeting the α2 receptors within the locus coeruleus. This action leads to significant inhibition of sympathetic excitation within the central nervous system resulting in sedative and anti-sympathetic effects. 4–6 A notable characteristic of its pharmacology is its ability to promote a natural sleep pattern allowing patients to be easily awakened from sedation, thereby achieving sedation while maintaining a relatively awake state without inducing significant respiratory depression. 7,8 Moreover, dexmedetomidine exhibits analgesic properties and can significantly reduce the requirement for opioids. 9 Extensive clinical evidence supports the safety and efficacy of dexmedetomidine across various clinical practices. Additionally, emerging research highlights its protective effects on organs subjected to ischemic and hypoxic injuries, including cardioprotection, neuroprotection, and nephroprotection. 10 As a peripheral adrenergic α2 receptor agonist, dexmedetomidine significantly modulates sympathetic nerve activity by competitively binding to peripheral norepinephrine (NE) receptors. Additionally, its high affinity for locus coeruleus cells in the nervous system enables it to reduce the synthesis of norepinephrine by these cells, thereby attenuating the effects of norepinephrine, a major catecholamine, through both source and receptor binding pathways. This mechanism allows dexmedetomidine to achi -Abstract Truncated-
health care sciences & services